Table 5. Patient characteristics according to their treatment/condition.
| Allogeneic HSCT (n=116) | Neutropenia (n=124) | IMV (n=196) | |
|---|---|---|---|
| Agea | 46 ± 13 | 53 ± 15 | 55 ± 16 |
| Sex(male)b | 69 (59) | 66 (53) | 105 (54) |
| Charlson scorea | 3.2 ± 1.5 | 3.7 ± 1.7 | 4.1 ± 2.1 |
| PSa | 2.1 ± 1.0 | 1.8 ± 0.9 | 2.0 ± 1.0 |
| Newly diagnosedb | NA | 43 (35) | 62 (32) |
| Autologous HSCTb | 23 (20) | 10 (8) | 17 (9) |
| Allogeneic HSCTb | NA | 38 (31) | 60 (31) |
| GVHDb | 60 (52) | 8 (6) | 32 (16) |
| Neutropeniab | 38 (33) | NA | 61 (31) |
| Respiratory distressb | 61 (53) | 54 (44) | 105 (56) |
| SOFAa | 8 ± 4 | 10 ± 3 | 10 ± 3 |
| IMVbc | 60 (52) | 61 (49) | NA |
| RRTbc | 29 (25) | 30 (24) | 69 (35) |
| Vasopressorbc | 48 (41) | 77 (62) | 137 (70) |
| SAPS IIa | 53 ± 22 | 66 ± 23 | 70 ± 26 |
| Day-28 mortalityb | 60 (52) | 67 (54) | 145 (74) |
| Day-90 mortalityb | 77 (66) | 80 (65) | 156 (80) |
| 1-year mortalityb | 94 (81) | 97 (78) | 171 (87) |
a
Data expressed as mean ± SD.
b
Data expressed as number (percentage).
c
Within the first 48 hours.
GVHD: graft versus host disease; HSCT: hematopoietic stem cell transplantation; IMV: invasive mechanical ventilation; PS: performance status; RRT: renal replacement therapy; SAPS II: simplified acute physiology score II; SOFA: sequential organ failure assessment.